FOXO4 10mg 10 Vials

Description

FOXO4-DRI Senolytic Peptide Targeting Cellular Senescence Research

Chemical Properties

• Amino Acid Sequence: L-TLMSQQLQPPTAPPPNPAMG-D (Retro-Inverso version)
• Molecular Formula: C182H301N47O53S2 (Approximate)
• Molecular Weight: ~5350 Da
• Purity: >99.0% via HPLC-UV and Mass Spectrometry
• Appearance: Fine white sterile lyophilizate

Mechanism Overview

The biochemical activity of FOXO4-DRI is defined by its ability to disrupt the protein-protein interaction between FOXO4 and the tumor suppressor p53. In senescent cells, FOXO4 sequesters p53 within the nucleus, preventing it from initiating apoptosis (programmed cell death). In the first phase, the DRI peptide competitively binds to the p53-interaction domain of endogenous FOXO4. This defines the first semantic triple: [FOXO4-DRI inhibits FOXO4-p53 binding]. Secondly, the release of p53 allows its translocation from the nucleus to the mitochondria. This establishes the second triple: [p53 translocation induces mitochondrial stress]. Thirdly, this mitochondrial signaling triggers the BAX/BAK-mediated apoptotic pathway specifically in senescent cells. This forms the third triple: [FOXO4-DRI induces selective senolysis]. Quantitatively, research models demonstrate that the removal of these cells reduces the systemic “SASP” (Senescence-Associated Secretory Phenotype).

Compound Background

FOXO4-DRI (D-Retro-Inverso) is a pioneering synthetic peptide designed to selectively target and eliminate senescent cells, often referred to as “zombie cells.” By utilizing a D-Retro-Inverso configuration, the peptide achieves superior resistance to proteolytic degradation compared to its L-amino acid counterparts. This signaling molecule serves as a critical research tool in the field of geroscience, investigating the reversal of age-related tissue dysfunction and the restoration of cellular homeostasis. [FOXO4-DRI targets senescent cells].

Experimental Outcomes

• Reversal of Frailty: Users in research models report significant improvements in physical activity levels and muscle coordination.
• Hair Follicle Rejuvenation: Anecdotal evidence based on the landmark 2017 study suggests the reactivation of dormant hair follicles and increased hair density.
• Enhanced Skin Elasticity: Per experimental records, research models show localized improvements in dermal thickness and collagen organization.
• Renal Function Support: Cumulative findings indicate a potential for reversing age-related kidney decline through the clearance of senescent tubular cells.
• Systemic Inflammation Reduction: Research models demonstrate a marked decrease in biomarkers of chronic low-grade inflammation (inflammaging).

Summary:
FOXO4-DRI represents a high-feasibility research tool for investigating the targeted elimination of senescent cells and the molecular mechanisms of biological rejuvenation.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.